Refine By

Stock Exchange

Market Cap (m)

Analyst

Sector

Type of Publication

targovax

1 - 2 of 2
Sort by: popularity | newest
Page  of 1
Targovax

Executive interview - Targovax

Edison TV: | Pharmaceutical & healthcare | 08 Nov 2017

In this short video Magnus Jaderberg, Chief Medical Officer of Targovax gives us some background on Targovax and discusses key technology areas.

Targovax

Priming immune response in anticancer combos

Initiation | Pharmaceutical & healthcare | 08 Nov 2017

Targovax is an immuno-oncology (IO) company specialising in two distinct, but complementary approaches. ONCOS-102 is a genetically engineered adenovirus being tested in advanced melanoma, mesothelioma and three other indications run by partners. From the TG platform two mutant RAS-specific, neo-antigen cancer vaccines are in development for colorectal and pancreatic cancers, for which interim Phase I/II results with positive survival data were presented at ASCO in June 2017. Targovax’s core proposition is to use its products as immune response primers and combine with other anticancer therapies, such as checkpoint inhibitors, for increased efficacy. We value Targovax at NOK1.69bn or NOK32.1 per share.